

Rosa Lombardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/937384/publications.pdf>

Version: 2024-02-01

58
papers

1,669
citations

304743

22
h-index

302126

39
g-index

58
all docs

58
docs citations

58
times ranked

2837
citing authors

#	ARTICLE	IF	CITATIONS
1	PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology, 2013, 19, 6969.	3.3	207
2	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 2017, 15, 1604-1611.e1.	4.4	146
3	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
4	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	3.7	107
5	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020, 296, 40-47.	0.8	78
6	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	2.2	75
7	Liver fibrosis by FibroScan [®] independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	3.9	59
8	Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. International Journal of Molecular Sciences, 2016, 17, 548.	4.1	58
9	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. Diabetes, Obesity and Metabolism, 2020, 22, 2408-2416.	4.4	58
10	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2019, 114, 916-928.	0.4	57
11	Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. Digestive and Liver Disease, 2019, 51, 1214-1222.	0.9	52
12	Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Digestive and Liver Disease, 2016, 48, 1471-1477.	0.9	45
13	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. International Journal of Endocrinology, 2015, 2015, 1-9.	1.5	41
14	The <i>UCP2</i> -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International, 2015, 35, 1574-1580.	3.9	41
15	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2345-2353.	2.6	40
16	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD). The Cochrane Library, 2017, 2017, CD011640.	2.8	36
17	Global Epidemiology of Hepatitis B Virus (HBV) Infection. Current Hepatology Reports, 2015, 14, 171-178.	0.9	31
18	Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2020, 21, 8761.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11044.	3.3	25
20	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , 2015, 26, 330-337.	2.2	25
21	Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. <i>Drugs and Aging</i> , 2016, 33, 53-61.	2.7	24
22	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. <i>Internal and Emergency Medicine</i> , 2013, 8, 509-520.	2.0	23
23	Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. <i>Atherosclerosis</i> , 2018, 268, 27-31.	0.8	19
24	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1135-1140.	0.9	18
25	Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 474-480.	2.1	18
26	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 535-549.	4.3	18
27	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 158523.	2.4	17
28	Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. <i>Annals of Gastroenterology</i> , 2017, 30, 349-356.	0.6	16
29	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. <i>Biomedicines</i> , 2022, 10, 249.	3.2	16
30	Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. <i>Biomedicines</i> , 2022, 10, 182.	3.2	15
31	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2015, 26, 243-249.	2.2	14
32	Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 800-806.	2.2	12
33	Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. <i>International Journal of Molecular Sciences</i> , 2016, 17, 675.	4.1	12
34	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 517-519.	4.4	12
35	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107684.	2.3	11
36	MAFLD and CKD: An Updated Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7007.	4.1	11

#	ARTICLE	IF	CITATIONS
37	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	2.0	10
38	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. <i>Nutrients</i> , 2022, 14, 556.	4.1	10
39	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2707.	4.1	9
40	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. <i>Liver International</i> , 2019, 39, 2309-2316.	3.9	8
41	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. <i>Journal of Internal Medicine</i> , 2022, 291, 374-376.	6.0	8
42	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. <i>Internal and Emergency Medicine</i> , 2015, 10, 305-313.	2.0	7
43	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021, 53, 1301-1307.	0.9	6
44	Extrapulmonary tuberculosis: an unusual presentation in an immunocompetent patient. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207146-bcr2014207146.	0.5	5
45	Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity. <i>Internal and Emergency Medicine</i> , 2022, 17, 1739-1749.	2.0	5
46	Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease. <i>Metabolic Brain Disease</i> , 2018, 33, 347-352.	2.9	4
47	Combined use of Genetic Polymorphisms and Elastographic Techniques in NAFLD: Fact or Fiction?. <i>Current Pharmaceutical Design</i> , 2020, 26, 1010-1018.	1.9	4
48	High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. <i>Digestive and Liver Disease</i> , 2020, 52, 84-90.	0.9	3
49	Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature. <i>Livers</i> , 2021, 1, 132-137.	1.9	2
50	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. <i>European Journal of Internal Medicine</i> , 2014, 25, 847-852.	2.2	1
51	Progressively invalidating orthostatic hypotension: A common symptom for a challenging diagnosis. <i>Journal of Research in Medical Sciences</i> , 2016, 21, 117.	0.9	1
52	Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 156-160.	1.5	1
53	Role of nutritional intake on clinical presentation of lean and overweight NAFLD. <i>Journal of Hepatology</i> , 2018, 68, S837.	3.7	0
54	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. <i>Journal of Hepatology</i> , 2019, 70, e302.	3.7	0

#	ARTICLE	IF	CITATIONS
55	Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis. Internal and Emergency Medicine, 2019, 14, 763-766.	2.0	0
56	A sweet fever. Internal and Emergency Medicine, 2019, 14, 1125-1128.	2.0	0
57	Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?. Digestive and Liver Disease, 2020, 52, 470-471.	0.9	0
58	Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Exploration of Medicine, 0, , .	1.5	0